Related Experiment Video
Updated: Sep 20, 2026

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Modulation of estrogen receptor activity by selective coregulators
Paolo G V Martini1, Benita S Katzenellenbogen
1Department of Molecular and Integrative Physiology, College of Medicine, University of Illinois, 524 Burrill Hall, 407 South Goodwin Avenue, Urbana, IL 61801, USA.
Abstract:
The estrogen receptor (ER), a member of the nuclear hormone receptor superfamily, is a hormone-regulated transcription factor that mediates the effects of estrogens and antiestrogens in breast cancer and other estrogen target cells. Because of the role of estrogens in promoting the growth and progression of breast cancer, there is great interest in exploring ways to functionally inactivate the ER, thereby suppressing ER-mediated gene expression and cell proliferation. These approaches have involved the use of antiestrogens such as tamoxifen, dominant negative ERs and, more recently, the use of corepressors. Through the use of two-hybrid screening, we have recently identified a selective repressor of estrogen receptor activity (REA). This protein is recruited to the hormone-occupied ER and selectively represses its transcriptional activity but not the other steroid and non-steroid nuclear receptors. REA also interacts with a protein, prothymosin-alpha (PTalpha), that selectively enhances ER transcriptional activity by recruiting the repressive REA protein away from ER. Analysis of the mechanisms underlying the activities of these two proteins highlights a new role for REA and PTalpha as activity-modulating proteins that confer receptor specificity.
Insights
Researchers discovered a new protein, repressor of estrogen receptor activity (REA), that selectively inhibits estrogen receptor (ER) activity. Prothymosin-alpha (PTalpha) counteracts REA, highlighting their roles in modulating ER specificity.
Area of Science:
- Molecular Biology
- Endocrinology
- Cancer Research
Background:
- Estrogen receptor (ER) is a key target in breast cancer therapy.
- ER mediates estrogen and antiestrogen effects in target cells.
- Inactivating ER is a strategy to suppress cancer growth.
Purpose of the Study:
- Identify novel regulators of estrogen receptor (ER) activity.
- Investigate the mechanism of selective ER repression.
- Explore the role of new proteins in modulating nuclear receptor function.
Main Methods:
- Two-hybrid screening to identify interacting proteins.
- Assays to measure transcriptional activity of nuclear receptors.
- Analysis of protein-protein interactions.
Main Results:
- Identified a selective repressor of estrogen receptor activity (REA).
- REA is recruited to the hormone-occupied ER, repressing its activity.
- Prothymosin-alpha (PTalpha) enhances ER activity by displacing REA.
Conclusions:
- REA selectively represses ER transcriptional activity.
- PTalpha enhances ER activity by modulating REA binding.
- REA and PTalpha act as novel modulators conferring ER specificity.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Co-activators and Co-repressors
Co-activators and Co-repressors
Regulation of Hormone Secretion
Humoral stimuli,...
Secondary Messengers in Hormone Action
Many hormones bind to transmembrane G protein-coupled receptors that connect to regulatory G proteins. These G proteins can then activate enzymes such as adenylyl cyclase or phospholipase C. Adenylyl cyclase converts ATP to cAMP, activating...
GPCRs Regulate Adenylyl Cylase Activity
Two...

